“C-POST protocol update: A Phase 3, randomized, double-blind study of adjuvant cemiplimab versus placebo post surgery and radiation therapy in patients with high-risk cutaneous squamous cell carcinoma”, J of Skin, vol. 7, no. 2, p. s173, Mar. 2023, doi: 10.25251/skin.7.supp.173.